DVAX has been the subject of several other research reports. ValuEngine lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. William Blair reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Tuesday, July 21st. Zacks Investment Research downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, July 8th. Cowen reaffirmed a “buy” rating and set a $20.00 target price on shares of Dynavax Technologies in a report on Friday, June 19th. Finally, Evercore ISI started coverage on Dynavax Technologies in a report on Monday, June 15th. They issued an “outperform” rating and a $14.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $13.88.
NASDAQ:DVAX opened at $8.11 on Friday. The company has a current ratio of 6.63, a quick ratio of 4.99 and a debt-to-equity ratio of 18.31. Dynavax Technologies has a one year low of $1.80 and a one year high of $12.44. The stock has a 50-day simple moving average of $8.41 and a 200 day simple moving average of $5.47.
Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). Dynavax Technologies had a negative return on equity of 722.75% and a negative net margin of 310.97%. The firm had revenue of $10.92 million for the quarter, compared to the consensus estimate of $10.91 million. Equities research analysts predict that Dynavax Technologies will post -0.95 earnings per share for the current fiscal year.
In other Dynavax Technologies news, Director Andrew A. F. Hack purchased 1,000,000 shares of Dynavax Technologies stock in a transaction on Wednesday, May 27th. The stock was bought at an average price of $4.84 per share, for a total transaction of $4,840,000.00. Also, SVP Robert Janssen sold 50,000 shares of the stock in a transaction on Friday, July 17th. The stock was sold at an average price of $11.09, for a total value of $554,500.00. Following the completion of the transaction, the senior vice president now directly owns 127,266 shares of the company’s stock, valued at approximately $1,411,379.94. The disclosure for this sale can be found here. Insiders have sold a total of 74,000 shares of company stock valued at $689,320 over the last three months. 13.33% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Avidity Partners Management LP increased its stake in Dynavax Technologies by 390.3% during the 1st quarter. Avidity Partners Management LP now owns 3,824,000 shares of the biopharmaceutical company’s stock valued at $13,499,000 after buying an additional 3,044,000 shares during the period. Deutsche Bank AG boosted its holdings in shares of Dynavax Technologies by 337.8% in the first quarter. Deutsche Bank AG now owns 1,049,701 shares of the biopharmaceutical company’s stock valued at $3,705,000 after acquiring an additional 809,934 shares in the last quarter. Chicago Capital LLC increased its stake in shares of Dynavax Technologies by 16.3% during the second quarter. Chicago Capital LLC now owns 4,904,695 shares of the biopharmaceutical company’s stock valued at $43,505,000 after acquiring an additional 689,170 shares during the period. Federated Hermes Inc. raised its holdings in Dynavax Technologies by 5.6% during the first quarter. Federated Hermes Inc. now owns 9,766,800 shares of the biopharmaceutical company’s stock worth $34,477,000 after purchasing an additional 520,000 shares in the last quarter. Finally, Blair William & Co. IL lifted its position in Dynavax Technologies by 18.6% in the first quarter. Blair William & Co. IL now owns 1,999,103 shares of the biopharmaceutical company’s stock worth $7,057,000 after purchasing an additional 313,946 shares during the period. 71.10% of the stock is owned by institutional investors and hedge funds.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Further Reading: Understanding the two types of arbitrage
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.